Financial Reports: Novo Nordisk 3Q

Posted on October 29, 2009 @ 09:59 am

Novo Nordisk 3Q09

3Q Revenues: $2.5 billion (+11%)

3Q Earnings: $539.7 million (+3%)

YTD Revenues: $7.4 billion (+16%)

YTD Earnings: $1.7 million (+21%)

Comments: In the quarter, Diabetes care sales were $1.8 billion (+12%). Biopharmaceutical sales were $636.3 (+10%). NovoSeven sales were up 8%, Norditropin sales were up 14%, and Hormone replacement therapy sales were up 12%. North America sales were up 20%. Sales in Europe were up 2%. International Operations were up 10% and Japan and Oceania sales were up 20%.